Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34352273)
Watch
English
Ibrutinib treatment of CLL: the cancer fights back
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
title
Ibrutinib treatment of CLL: the cancer fights back
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
main subject
ibrutinib
1 reference
based on heuristic
inferred from title
author name string
Ryan M Young
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
Louis M Staudt
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
publication date
1 July 2014
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
published in
Cancer Cell
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
volume
26
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
issue
1
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
page(s)
11-13
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
cites work
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Ibrutinib resistance in chronic lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Targeting pathological B cell receptor signalling in lymphoid malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4199743
retrieved
6 July 2018
Identifiers
DOI
10.1016/J.CCR.2014.06.023
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
PMCID
4199743
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
PubMed ID
25026208
1 reference
stated in
Europe PubMed Central
PubMed ID
25026208
retrieved
1 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
